In contrast, i.t. injection of 111In-labeled HER2-targeted AuNPs resulted in 25-fold greater tumour uptake (29.6% ID/g) and decreased spleen uptake by 11-fold (1.8% ID/g) while moderately reducing uptake in the liver (1.6% ID/g) and kidneys (1.5% ID/g). Here, ERBB2 is linked to neoplasm.